Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 972193, 9 pages
http://dx.doi.org/10.1155/2015/972193
Review Article

Breast Cancer Metabolism and Mitochondrial Activity: The Possibility of Chemoprevention with Metformin

Division of Cancer Prevention and Genetics, European Institute of Oncology, 20141 Milan, Italy

Received 27 May 2015; Revised 11 September 2015; Accepted 7 October 2015

Academic Editor: Yunfeng Zhao

Copyright © 2015 Massimiliano Cazzaniga and Bernardo Bonanni. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Byler, S. Goldgar, S. Heerboth et al., “Genetic and epigenetic aspects of breast cancer progression and therapy,” Anticancer Research, vol. 34, no. 3, pp. 1071–1077, 2014. View at Google Scholar · View at Scopus
  2. S. Romero-Garcia, J. S. Lopez-Gonzalez, J. L. Báez-Viveros, D. Aguilar-Cazares, and H. Prado-Garcia, “Tumor cell metabolism: an integral view,” Cancer Biology and Therapy, vol. 12, no. 11, pp. 939–948, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. W. H. Koppenol, P. L. Bounds, and C. V. Dang, “Otto Warburg's contributions to current concepts of cancer metabolism,” Nature Reviews Cancer, vol. 11, no. 5, pp. 325–337, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. M. G. V. Heiden, L. C. Cantley, and C. B. Thompson, “Understanding the warburg effect: the metabolic requirements of cell proliferation,” Science, vol. 324, no. 5930, pp. 1029–1033, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Pfeiffer, S. Schuster, and S. Bonhoeffer, “Cooperation and competition in the evolution of ATP-producing pathways,” Science, vol. 292, no. 5516, pp. 504–507, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. O. Warburg, “On the origin of cancer cells,” Science, vol. 123, no. 3191, pp. 309–314, 1956. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Moreno-Sánchez, S. Rodríguez-Enríquez, A. Marín-Hernández, and E. Saavedra, “Energy metabolism in tumor cells,” FEBS Journal, vol. 274, no. 6, pp. 1393–1418, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. I. A. Barbosa, N. G. Machado, A. J. Skildum, P. M. Scott, and P. J. Oliveira, “Mitochondrial remodeling in cancer metabolism and survival: potential for new therapies,” Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, vol. 1826, no. 1, pp. 238–254, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. Á. D. Ortega, M. Sánchez-Aragó, D. Giner-Sánchez, L. Sánchez-Cenizo, I. Willers, and J. M. Cuezva, “Glucose avidity of carcinomas,” Cancer Letters, vol. 276, no. 2, pp. 125–135, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. N. D. Amoêdo, J. P. Valencia, M. F. Rodrigues, A. Galina, and F. D. Rumjanek, “How does the metabolism of tumour cells differ from that of normal cells,” Bioscience Reports, vol. 33, no. 6, pp. 865–873, 2013. View at Google Scholar · View at Scopus
  11. J. Zheng, “Energy metabolism of cancer: glycolysis versus oxidative phosphorylation (review),” Oncology Letters, vol. 4, no. 6, pp. 1151–1157, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Patergnani, F. Baldassari, E. De Marchi, A. Karkucinska-Wieckowska, M. R. Wieckowski, and P. Pinton, “Methods to monitor and compare mitochondrial and glycolytic ATP production,” Methods in Enzymology, vol. 542, pp. 313–332, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Bonuccelli, A. Tsirigos, D. Whitaker-Menezes et al., “Ketones and lactate ‘fuel’ tumor growth and metastasis: evidence that epithelial cancer cells use oxidative mitochondrial metabolism,” Cell Cycle, vol. 9, no. 17, pp. 3506–3514, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Rodríguez-Enríquez, L. Carreño-Fuentes, J. C. Gallardo-Pérez et al., “Oxidative phosphorylation is impaired by prolonged hypoxia in breast and possibly in cervix carcinoma,” International Journal of Biochemistry & Cell Biology, vol. 42, no. 10, pp. 1744–1751, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. L. M. R. Ferreira, “Cancer metabolism: the Warburg effect today,” Experimental and Molecular Pathology, vol. 89, no. 3, pp. 372–380, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. M. López-Lázaro, “The warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen?” Anti-Cancer Agents in Medicinal Chemistry, vol. 8, no. 3, pp. 305–312, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. R. J. DeBerardinis, J. J. Lum, G. Hatzivassiliou, and C. B. Thompson, “The biology of cancer: metabolic reprogramming fuels cell growth and proliferation,” Cell Metabolism, vol. 7, no. 1, pp. 11–20, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. P. S. Ward and C. B. Thompson, “Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate,” Cancer Cell, vol. 21, no. 3, pp. 297–308, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. E. Laconi, “The evolving concept of tumor microenvironments,” BioEssays, vol. 29, no. 8, pp. 738–744, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. A. L. Harris, “Hypoxia—a key regulatory factor in tumour growth,” Nature Reviews Cancer, vol. 2, no. 1, pp. 38–47, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. G. L. Semenza, “Targeting HIF-1 for cancer therapy,” Nature Reviews Cancer, vol. 3, no. 10, pp. 721–732, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Y. C. Choi, C. C. Collins, P. W. Gout, and Y. Wang, “Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite?” The Journal of Pathology, vol. 230, no. 4, pp. 350–355, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Mayer and P. Vaupel, “Hypoxia, lactate accumulation, and acidosis: siblings or accomplices driving tumor progression and resistance to therapy?” Advances in Experimental Medicine and Biology, vol. 789, pp. 203–209, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. R. A. Gatenby, K. Smallbone, P. K. Maini et al., “Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer,” British Journal of Cancer, vol. 97, no. 5, pp. 646–653, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Mekhail, L. Rivero-Lopez, M. Khacho, and S. Lee, “Restriction of rRNA synthesis by VHL maintains energy equilibrium under hypoxia,” Cell Cycle, vol. 5, no. 20, pp. 2401–2413, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Laplante and D. M. Sabatini, “MTOR signaling in growth control and disease,” Cell, vol. 149, no. 2, pp. 274–293, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. D. Daye and K. E. Wellen, “Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis,” Seminars in Cell & Developmental Biology, vol. 23, no. 4, pp. 362–369, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. D. R. Wise, R. J. Deberardinis, A. Mancuso et al., “Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 48, pp. 18782–18787, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. J.-B. Wang, J. W. Erickson, R. Fuji et al., “Targeting mitochondrial glutaminase activity inhibits oncogenic transformation,” Cancer Cell, vol. 18, no. 3, pp. 207–219, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Gao, I. Tchernyshyov, T.-C. Chang et al., “c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism,” Nature, vol. 458, no. 7239, pp. 762–765, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. M. R. Reynolds, A. N. Lane, B. Robertson et al., “Control of glutamine metabolism by the tumor suppressor Rb,” Oncogene, vol. 33, no. 5, pp. 556–566, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. P. L. Pedersen, “Tumor mitochondria and the bioenergetics of cancer cells,” Progress in Experimental Tumor Research, vol. 22, pp. 190–274, 1978. View at Google Scholar
  33. M. Škrtić, S. Sriskanthadevan, B. Jhas et al., “Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia,” Cancer Cell, vol. 20, no. 5, pp. 674–688, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. D. R. Wise and C. B. Thompson, “Glutamine addiction: a new therapeutic target in cancer,” Trends in Biochemical Sciences, vol. 35, no. 8, pp. 427–433, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. F. Weinberg and N. S. Chandel, “Mitochondrial metabolism and cancer,” Annals of the New York Academy of Sciences, vol. 1177, pp. 66–73, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. R. W. Taylor and D. M. Turnbull, “Mitochondrial DNA mutations in human disease,” Nature Reviews Genetics, vol. 6, no. 5, pp. 389–402, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. R. Scatena, “Mitochondria and cancer: a growing role in apoptosis, cancer cell metabolism and dedifferentiation,” Advances in Experimental Medicine and Biology, vol. 942, pp. 287–308, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. P. J. Pollard, J. J. Brière, N. A. Alam et al., “Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations,” Human Molecular Genetics, vol. 14, no. 15, pp. 2231–2239, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. K. Bensaad and K. H. Vousden, “p53: new roles in metabolism,” Trends in Cell Biology, vol. 17, no. 6, pp. 286–291, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. S. J. Yeung, J. Pan, and M.-H. Lee, “Roles of p53, MYC and HIF-1 in regulating glycolysis—the seventh hallmark of cancer,” Cellular and Molecular Life Sciences, vol. 65, no. 24, pp. 3981–3999, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. R. Scatena, P. Bottoni, A. Pontoglio, L. Mastrototaro, and B. Giardina, “Glycolytic enzyme inhibitors in cancer treatment,” Expert Opinion on Investigational Drugs, vol. 17, no. 10, pp. 1533–1545, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Fulda, L. Galluzzi, and G. Kroemer, “Targeting mitochondria for cancer therapy,” Nature Reviews Drug Discovery, vol. 9, no. 6, pp. 447–464, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. E. Zhang, C. Zhang, Y. Su, T. Cheng, and C. Shi, “Newly developed strategies for multifunctional mitochondria-targeted agents in cancer therapy,” Drug Discovery Today, vol. 16, no. 3-4, pp. 140–146, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. D. Whitaker-Menezes, U. E. Martinez-Outschoorn, N. Flomenberg et al., “Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue,” Cell Cycle, vol. 10, no. 23, pp. 4047–4064, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Becker, L. Dossus, and R. Kaaks, “Obesity related hyperinsulinaemia and hyperglycaemia and cancer development,” Archives of Physiology and Biochemistry, vol. 115, no. 2, pp. 86–96, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Esposito, P. Chiodini, A. Colao, A. Lenzi, and D. Giugliano, “Metabolic syndrome and risk of cancer: a systematic review and meta-analysis,” Diabetes Care, vol. 35, no. 11, pp. 2402–2411, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. K. Esposito, P. Chiodini, A. Capuano et al., “Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis,” Menopause, vol. 20, no. 12, pp. 1301–1309, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. H. Cheong, C. Lu, T. Lindsten, and C. B. Thompson, “Therapeutic targets in cancer cell metabolism and autophagy,” Nature Biotechnology, vol. 30, no. 7, pp. 671–678, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. M. G. Vander Heiden, “Targeting cancer metabolism: a therapeutic window opens,” Nature Reviews Drug Discovery, vol. 10, no. 9, pp. 671–684, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. A. DeCensi, M. Puntoni, P. Goodwin et al., “Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis,” Cancer Prevention Research, vol. 3, no. 11, pp. 1451–1461, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Cazzaniga, B. Bonanni, A. Guerrieri-Gonzaga, and A. Decensi, “Is it time to test metformin in breast cancer clinical trials?” Cancer Epidemiology Biomarkers & Prevention, vol. 18, no. 3, pp. 701–705, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. B. Bonanni, M. Puntoni, M. Cazzaniga et al., “Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial,” Journal of Clinical Oncology, vol. 30, no. 21, pp. 2593–2600, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. A. F. G. Cicero, E. Tartagni, and S. Ertek, “Metformin and its clinical use: new insights for an old drug in clinical practice,” Archives of Medical Science, vol. 8, no. 5, pp. 907–917, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Suissa and L. Azoulay, “Metformin and cancer: mounting evidence against an association,” Diabetes Care, vol. 37, no. 7, pp. 1786–1788, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. C. Bosetti, M. Franchi, F. Nicotra et al., “Insulin and other antidiabetic drugs and hepatocellular carcinoma risk: a nested case-control study based on Italian healthcare utilization databases,” Pharmacoepidemiology and Drug Safety, vol. 24, no. 7, pp. 771–778, 2015. View at Publisher · View at Google Scholar
  56. I. Pernicova and M. Korbonits, “Metformin—mode of action and clinical implications for diabetes and cancer,” Nature Reviews Endocrinology, vol. 10, no. 3, pp. 143–156, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. R. J. O. Dowling, S. Niraula, M. C. Chang et al., “Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study,” Breast Cancer Research, vol. 17, article 32, 2015. View at Publisher · View at Google Scholar
  58. G. Zhou, R. Myers, Y. Li et al., “Role of AMP-activated protein kinase in mechanism of metformin action,” The Journal of Clinical Investigation, vol. 108, no. 8, pp. 1167–1174, 2001. View at Publisher · View at Google Scholar · View at Scopus
  59. F. M. Giardiello, J. D. Brensinger, A. C. Tersmette et al., “Very high risk of cancer in familial Peutz-Jeghers syndrome,” Gastroenterology, vol. 119, no. 6, pp. 1447–1453, 2000. View at Publisher · View at Google Scholar · View at Scopus
  60. S. M. Hadad, P. Coates, L. B. Jordan et al., “Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial,” Breast Cancer Research and Treatment, vol. 150, no. 1, pp. 149–155, 2015. View at Publisher · View at Google Scholar · View at Scopus
  61. D. G. Hardie and D. R. Alessi, “LKB1 and AMPK and the cancer-metabolism link—ten years after,” BMC Biology, vol. 11, article 36, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. B. Faubert, G. Boily, S. Izreig et al., “AMPK is a negative regulator of the warburg effect and suppresses tumor growth in vivo,” Cell Metabolism, vol. 17, no. 1, pp. 113–124, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. J. G. Boyle, I. P. Salt, and G. A. McKay, “Metformin action on AMP-activated protein kinase: a translational research approach to understanding a potential new therapeutic target,” Diabetic Medicine, vol. 27, no. 10, pp. 1097–1106, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. J. Liang, S. H. Shao, Z.-X. Xu et al., “The energy sensing LKB1-AMPK pathway regulates p27kip1 phosphorylation mediating the decision to enter autophagy or apoptosis,” Nature Cell Biology, vol. 9, no. 2, pp. 218–224, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. C. Algire, L. Amrein, M. Bazile, S. David, M. Zakikhani, and M. Pollak, “Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo,” Oncogene, vol. 30, no. 10, pp. 1174–1182, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. L. Galluzzi, O. Kepp, and G. Kroemer, “TP53 and MTOR crosstalk to regulate cellular senescence,” Aging, vol. 2, no. 9, pp. 535–537, 2010. View at Google Scholar · View at Scopus
  67. M. C. Maiuri, L. Galluzzi, E. Morselli, O. Kepp, S. A. Malik, and G. Kroemer, “Autophagy regulation by p53,” Current Opinion in Cell Biology, vol. 22, no. 2, pp. 181–185, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. S. Pavlides, D. Whitaker-Menezes, R. Castello-Cros et al., “The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma,” Cell Cycle, vol. 8, no. 23, pp. 3984–4001, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. U. E. Martinez-Outschoorn, R. G. Pestell, A. Howell et al., “Energy transfer in ‘parasitic’ cancer metabolism: mitochondria are the powerhouse and Achilles' heel of tumor cells,” Cell Cycle, vol. 10, no. 24, pp. 4208–4216, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. U. E. Martinez-Outschoorn, M. Prisco, A. Ertel et al., “Ketones and lactate increase cancer cell ‘stemness’, driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via metabolo-genomics,” Cell Cycle, vol. 10, no. 8, pp. 1271–1286, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. A. Vazquez-Martin, E. López-Bonetc, S. Cufí et al., “Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions,” Drug Resistance Updates, vol. 14, no. 4-5, pp. 212–223, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Rice, L. Pellat, A. Ahmetaga, G. Bano, H. Mason, and S. Whitehead, “Dual effect of metformin on growth inhibition and oestradiol production in breast cancer cells,” International Journal of Molecular Medicine, vol. 35, no. 4, pp. 1088–1094, 2015. View at Publisher · View at Google Scholar
  73. C. Fan, Y. Wang, Z. Liu et al., “Metformin exerts anticancer effects through the inhibition of the Sonic hedgehog signaling pathway in breast cancer,” International Journal of Molecular Medicine, vol. 36, no. 1, pp. 204–214, 2015. View at Publisher · View at Google Scholar
  74. P. J. Goodwin, W. R. Parulekar, K. A. Gelmon et al., “Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32,” Journal of the National Cancer Institute, vol. 107, no. 3, Article ID djv006, 2015. View at Publisher · View at Google Scholar
  75. A. DeCensi, M. Puntoni, S. Gandini et al., “Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial,” Breast Cancer Research and Treatment, vol. 148, no. 1, pp. 81–90, 2014. View at Publisher · View at Google Scholar · View at Scopus
  76. J. Kim, W. Lim, E.-K. Kim et al., “Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR),” BMC Cancer, vol. 14, article 170, 2014. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Cazzaniga, A. DeCensi, G. Pruneri et al., “The effect of metformin on apoptosis in a breast cancer presurgical trial,” British Journal of Cancer, vol. 109, no. 11, pp. 2792–2797, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. S. Niraula, R. J. O. Dowling, M. Ennis et al., “Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study,” Breast Cancer Research and Treatment, vol. 135, no. 3, pp. 821–830, 2012. View at Publisher · View at Google Scholar · View at Scopus
  79. A. F. Santidrian, A. Matsuno-Yagi, M. Ritland et al., “Mitochondrial complex I activity and NAD+/NADH balance regulate breast cancer progression,” The Journal of Clinical Investigation, vol. 123, no. 3, pp. 1068–1081, 2013. View at Publisher · View at Google Scholar
  80. A. F. Salem, D. Whitaker-Menezes, A. Howell, F. Sotgia, and M. P. Lisanti, “Mitochondrial biogenesis in epithelial cancer cells promotes breast cancer tumor growth and confers autophagy resistance,” Cell Cycle, vol. 11, no. 22, pp. 4174–4180, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. W. W. Wheaton, S. E. Weinberg, R. B. Hamanaka et al., “Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis,” eLife, vol. 3, Article ID e02242, 2014. View at Publisher · View at Google Scholar
  82. A. Emami Riedmaier, P. Fisel, A. T. Nies, E. Schaeffeler, and M. Schwab, “Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects,” Trends in Pharmacological Sciences, vol. 34, no. 2, pp. 126–135, 2013. View at Publisher · View at Google Scholar · View at Scopus
  83. L. M. Berstein, A. G. Iyevleva, D. Vasilyev, T. E. Poroshina, and E. N. Imyanitov, “Genetic polymorphisms potentially associated with response to metformin in postmenopausal diabetics suffering and not suffering with cancer,” Cell Cycle, vol. 12, no. 23, pp. 3681–3688, 2013. View at Publisher · View at Google Scholar · View at Scopus
  84. Y. Shu, S. A. Sheardown, C. Brown et al., “Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action,” The Journal of Clinical Investigation, vol. 117, no. 5, pp. 1422–1431, 2007. View at Publisher · View at Google Scholar · View at Scopus
  85. X. Lin, C. A. David, J. B. Donnelly et al., “A chemical genomics screen highlights the essential role of mitochondria in HIF-1 regulation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 1, pp. 174–179, 2008. View at Publisher · View at Google Scholar · View at Scopus